The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment ...

Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...

Compared with digital mammography, 3D mammography (or tomosynthesis) reduces recall rates and improves specificity in women ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...